

IN THE CLAIMS:

Please amend the claims as follows:

1-131. (Cancelled)

Please add the following new claims:

132. (New) A method for the treatment of an angiogenesis-related disorder, comprising modulating the expression or activity of a BNO802 polypeptide encoded by a BNO802 nucleic acid molecule set forth in Table 1.

133. (New) The method of claim 132, wherein the expression or activity of the BNO802 polypeptide is modulated by introducing into the cell an antagonist or agonist of the BNO802 nucleic acid molecule or an antagonist or agonist of the BNO802 polypeptide.

134. (New) The method of claim 132, wherein the expression or activity of the BNO802 polypeptide is modulated by introducing into the cell an antisense to the BNO802 nucleic acid molecule.

135. (New) The method of claim 132, wherein the expression or activity of the BNO802 polypeptide is modulated by introducing into the cell a nucleic acid which is the complement of at least a portion of the BNO802 nucleic acid molecule and is capable of modulating expression or levels of the BNO802 nucleic acid molecule.

136. (New) The method of claim 135, wherein the nucleic acid is an RNA molecule that hybridizes with the mRNA encoded by the BNO802 nucleic acid molecule.

137. (New) The method of claim 135, wherein the nucleic acid is a short interfering oligonucleotide that hybridizes with the mRNA encoded by the BNO802 nucleic acid molecule.

138. (New) The method of claim 135, wherein the nucleic acid is a catalytic nucleic acid that is targeted to the BNO802 nucleic acid molecule.

139. (New) The method of claim 138, wherein the catalytic nucleic acid is a DNAzyme.

140. (New) The method of claim 138, wherein the catalytic nucleic acid is a ribozyme.

141. (New) The method of claim 132, wherein the expression or activity of the BNO802 polypeptide is modulated by an antibody capable of binding the BNO802 polypeptide.

142. (New) The method of claim 141, wherein the antibody is a full human antibody.

143. (New) The method of claim 141, wherein the antibody is selected from the group consisting of a monoclonal antibody, a humanised antibody, a chimaeric antibody or an antibody fragment including a Fab fragment, (Fab')₂ fragment, Fv fragment, single chain antibodies and single domain antibodies.

144. (New) The method of claim 132, wherein the expression or activity of the BNO802 polypeptide is modulated by introducing into the cell a BNO802 nucleic acid molecule set forth in Table 1.

145. (New) The method of claim 132, wherein the expression or activity of the BNO802 polypeptide is modulated by introducing into the cell a BNO802 polypeptide set forth in Table 1.

146. (New) The method of claim 132, wherein the disorder is selected from the group consisting of cancer, rheumatoid arthritis, diabetic retinopathy, psoriasis, cardiovascular diseases such as atherosclerosis, ischaemic limb disease or coronary artery disease.

RESTRICTION PRESENTED

The claims have been restricted into the following groups of inventions:

Group	Claims	Subject Matter
I	1-4	Drawn to method for the identification of a nucleic acid molecule differentially expressed in an <i>in vitro</i> model;
II	5 and 6	Drawn to a method for the identification of a nucleic acid molecule up-regulated in an <i>in vitro</i> model;
III	7, 8, 10-17, 20, and 112-115	Drawn to a nucleic acid molecule, a gene, a short interfering oligonucleotide, and a catalytic nucleic acid;
IV	9	Drawn to polypeptide;
V	18 and 19	Drawn to use of a nucleic acid to identify and/or obtain full length human genes involved in an angiogenic process;
VI	28	Drawn to an expression vector, a transformed cell, and a method of preparing a polypeptide;
VII	116	Drawn to use of a nucleic acid in the diagnosis or prognosis of an angiogenesis related disorder; and
VIII	128-131	Drawn to a genetically modified non human animal.